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120Emergency endovascular stent grafting in acute
complicated type B dissection
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Objective: The objective of this study was to assess midterm results of emergency endovascular stent grafting for patients
with life-threatening complications of acute type B aortic dissection.
Methods: BetweenMarch 1999 and November 2011, 110 patients (86 men, 24 women) with complications of acute type B
aortic dissection (mean age, 61 years; range, 19-87 years) were treated with thoracic endovascular aortic repair for
malperfusion (55.5%) or aortic rupture (53.6%) in ﬁve major European referral centers and one U.S. referral center.
Additional comorbidities included hypertension in 90 patients (82%), diabetes in 14 patients (13%), and chronic
obstructive pulmonary disease in six patients (6%). Eleven patients (10%) had undergone previous aortic surgery.
Results: Overall hospital mortality was 12% (n [ 13), with 14 late deaths after hospital discharge. In-hospital compli-
cations occurred in 32 patients (36%); 10 patients developed postoperative renal failure, ﬁve patients experienced new
permanent neurologic symptoms, and six patients (5.4%) experienced retrograde type A aortic dissection. Furthermore,
nine patients (8%) developed an early type I endoleak. Actuarial survival at 1 and 5 years was 85% and 73%, respectively.
Postprocedural computed tomography angiography showed complete or partial thrombosis of the false lumen at the stent
graft level in 61% and 23% of all patients, respectively. Freedom from treatment failure according to the Stanford clas-
siﬁcation was 82%, 75%, and 59% at 1, 3, and 5 years.
Conclusions: Endovascular repair of complicated acute type B aortic dissection is proven to be a technically feasible and
effective treatment modality in this relatively difﬁcult patient cohort. Short-term and midterm results are persuasive;
however, the long-term efﬁcacy needs to be further evaluated. (J Vasc Surg 2014;60:1204-8.)Acute type B aortic dissection is an uncommon
condition. However, when it occurs, it remains a formi-
dable challenge for cardiac and vascular surgeons as well
as in recent years for interventional radiologists. In the
United States, between 5 and 10 people per million per
year experience an aortic dissection, with 43,000 to
47,000 deaths from involvement of the aorta and its
branches.1 The optimal management of patients with Stan-
ford type B dissections remains a matter of ongoing debate.
Patients with malperfusion or rupture are especially at high
risk.2,3 Emergency treatment options include open surgical
thoracic aortic graft replacement, interventional or surgical
ﬂap fenestration and true lumen stenting, catheter reperfu-
sion or extra-anatomic surgical bypass, and thoracic endo-
vascular aortic repair (TEVAR).4 Contemporary mortalitythe Department of Cardiac Surgery, Medical University of Vienna,
iennaa; the Department of Vascular Surgery, Hôpital de la Timone,
arseilleb; the Cardiovascular Department, Unit of Cardiovascular
adiology, University Hospital S. Orsola, Bolognac; the Department of
adiology, University Hospital Rangueil, Touloused; the Department
Cardiology, General Hospital Vall d’Hebron, Barcelonae; and the
ivision of Cardiovascular Surgery, University of Pennsylvania Medical
enter, Philadelphia.f
or conﬂict of interest: none.
rint requests: Dominik Wiedemann, MD, Vienna Medical University,
epartment of Cardiac Surgery, Währinger Gürtel 18-20, Vienna, Austria
-mail: dominik.wiedemann@meduniwien.ac.at).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2014.06.001
4rates of surgical resection of acute complicated type B dis-
sections range between 15% and 30% in complicated cases
under emergency conditions. Therefore, acute complicated
type B dissections are increasingly treated by endovascular
aortic repair.5
During the last decade, endovascular techniques have
revolutionized the management of descending thoracic
aortic disease, with the beneﬁt of exclusion of the patho-
logically altered aorta without direct surgical exposure.
Nevertheless, in the United States, the Food and Drug
Administration labeled only one TEVAR device (Gore
TAG in 2013) for type B dissection, descending thoracic
aneurysms, and penetrating aortic ulcers. Reports on the
outcome of complicated type B aortic dissection in the
literature are scarce. Most of the studies are single-center
experiences with a relatively low number of patients
included. Nevertheless, preliminary results suggest that
salvage rates are higher than what would be expected if sur-
gical approaches had been used.1,6-9 On the basis of these
results, the indications for TEVAR are expected to expand
in the future. Prospective randomized clinical trials
comparing the treatment of patients with acute compli-
cated type B aortic dissection with TEVAR vs open surgical
thoracic aortic repair would be impractical in this high-risk
patient group, and it would be difﬁcult to get comparable
cohorts including enough patients. So far, the multicenter
reports on this study are scarce.2 This analysis of ﬁve sites in
the United States including 99 patients with complicated
type B aortic dissection showed acceptable results of
TEVAR, with 30-day mortality rates of 10.8%. The aim
of this study was to assess the early and midterm results
Table I. Demographics
No. (%)
Male gender 86 (78.2)
Female gender 24 (21.8)
Median age (range), years 61 (19-87)
Marfan syndrome 0
Diabetes 14 (12.7)
History of cancer 1 (0.9)
Previous cerebrovascular injury 4 (3.6)
Chronic obstructive pulmonary disease 6 (5.5)
Arterial hypertension 90 (81.8)
Renal failure requiring dialysis 2 (1.8)
History of myocardial infarction 7 (6.4)
Smoker 14 (12.7)
Previous aortic surgery 11 (10)
Previous cardiac surgery 3 (2.7)
Data are presented as number (%) unless otherwise indicated.
Table II. Stent manufacturer
No. (%)
Talent 46 (41.8)
Thoracic Excluder 53 (48.1)
Relay 4 (3.6)
Zenith 4 (3.6)
Hemashield 1 (0.9)
Valiant 1 (0.9)
Manufacturer not documented 1 (0.9)
Table III. Complications
No. (%)
Postinterventional complications 32 (36)
Retrograde type A dissection 6 (5.4)
Postinterventional renal failure 10 (9)
New permanent neurologic deﬁcit 5 (4.5)
Mesenteric ischemia 2 (1.8)
Gastrointestinal bleeding 3 (2.7)
Hemothorax/secondary rupture 3 (2.7)
Liver malperfusion 1 (0.9)
Lower limb ischemia 2 (1.8)
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the data of six different sites.
METHODS
The data of six sites (ﬁvemajor European referral centers
and one U.S. referral center) were prospectively collected
and retrospectively analyzed. Between March 1999 and
November 2011, 110 patients (86 men, 24 women) with
complications of acute type B aortic dissection (mean age,
61 years; range, 19-87 years) were treated with TEVAR.
Within this multicenter analysis, the data of two high-
volume centers (n ¼ 52, n ¼ 37) and four lower volume
centers (n ¼ 7, n ¼ 6, n ¼ 6, n ¼ 2) were included. Basic
demographics of these patient cohorts are shown in Table I.
Hypertension was the most frequent comorbidity and was
seen in 90 patients (82%), followed by diabetes in 14 patients
(13%) and chronic obstructive pulmonary disease in six pa-
tients (6%). Eleven patients (10%) had undergone previous
aortic surgery. All patients gave informed consent for the pro-
cedure apart from those patients who were not able to give
informed consent at the time of intervention (emergency
procedure/intubated patient). Institutional Review Board
approvalwas either givenorwaiveddependingon the require-
ment of each center’s Institutional Review Board.
Deﬁnitions. Type B aortic dissection was deﬁned as
complicated if malperfusion, aortic rupture, or both were
present. Within this study, we did not regard persistent
or recurrent pain as a criterion for a complicated type B
aortic dissection.
Rupture was deﬁned by hemorrhage outside of the
aortic boundaries. Malperfusion was deﬁned as one or
more of the following: intestinal malperfusion, renal mal-
perfusion, lower extremity malperfusion, or spinal cord
malperfusion. All patients were treated by a multidisci-
plinary team (interventional radiology, anesthesia, and car-
diac or vascular surgery).
Treatment failure was deﬁned according to the Stan-
ford criteria as aortic rupture, device mechanical fault,
any kind of reintervention, aorta-related death, or sudden
or unexplained late death.1,8Endovascular prosthesis and procedure. All patients
were treated with commercially available stent grafts. The
Talent endoprosthesis (Medtronic, Sunrise, Fla) was used
in 46 patients; the thoracic Excluder (W. L. Gore & Asso-
ciates, Flagstaff, Ariz), in 53 patients; the Relay system
(Bolton Medical, Sunrise, Fla), in four patients; the Zenith
system (Cook Medical, Bloomington, Ind), in four pa-
tients; the Hemashield (Boston Scientiﬁc, Fremont, Calif),
in one patient; and the Valiant device (Medtronic), in one
patient. The stent manufacturer was not documented in
one case (Table II). Stent graft diameter was calculated
from the largest diameter of the proximal landing zone,
adding an oversizing factor of 10% to 20%.
The centers included in this study regard an acute
complicated type B dissection as a primary indication for
stent graft placement. Within the study period, no patient
primarily underwent open surgery regardless of the landing
zone. Of course, a proximal landing zone of more than
2 cm would be desirable, but we think that the risk of
open surgery still is higher than the risk of stent graft place-
ment in this cohort. If the landing zone was less than 2 cm,
if possible, either an overstenting of the left subclavian ar-
tery was performed or some kind of rerouting maneuver
was the method of choice. Fenestrations were performed
only as an additional procedure but not as the only proce-
dure within this study.
Statistical analysis. Continuous variables are shown as
median and range, with categorical variables as number and
percentage. Kaplan-Meier analysis was used for survival
analysis and for analysis of freedom from treatment failure.
RESULTS
Overall in-hospital mortality was 12% (n¼ 13). Relevant
in-hospital complications occurred in 32 patients (36%);
Table IV. Status at presentation
No. (%)
Malperfusion 61 (55.5)
Rupture 59 (53.6)
Pain at onset 43 (39.1)
Unstable at presentation 74 (67.3)
Intubated 4 (3.6)
Paralysis before intervention 0
Paraparesis before intervention 1 (0.9)
Table V. Interventional variables and postinterventional
outcome
No. (%)
Femoral access 106 (96.4)
Iliac access 4 (3.6)
Median number of stents (range) 1.5 (1-4)
Overstenting of subclavian artery 19 (17.3)
Surgical intervention/conversion 12 (10.9)
In-hospital death 13 (11.8)
Early endoleak 9 (8)
Late endoleak 8 (7.3)
Complete thoracic false lumen thrombosis 67 (60.9)
Partial thoracic false lumen thrombosis 25 (22.7)
Complete abdominal false lumen thrombosis 8 (7.3)
Partial abdominal false lumen thrombosis 26 (23.6)
Data are presented as number (%) unless otherwise indicated.
Table VII. Surgical interventions
No. (%)
Surgical interventions/conversions 11 (10)
Repair of retrograde type A dissection 6 (5.4)
Thoracoabdominal aortic replacement 2 (1.8)
Thoracotomy due to hemothorax 2 (1.8)
Small bowel resection 1 (0.9)
Table VI. Additional procedures
No. (%)
Additional procedures 15 (13.6)
Second aortic stent procedure 6 (5.4)
Iliac stenting 2 (1.8)
Fenestration 2 (1.8)
Left subclavian transposition 1 (0.9)
Arch debranching 1 (0.9)
Carotid-subclavian bypass 1 (0.9)
Infrarenal aortic replacement 1 (0.9)
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tion (5.4%), 10 patients developed postoperative renal
failure, and ﬁve patients developed new permanent neuro-
logic deﬁcits. The other complications included mesen-
teric ischemia, gastrointestinal bleedings, hemothorax/
intrathoracic bleeding, liver malperfusion, lower limb
ischemia resulting in limb amputation, and septicemia
(Table III).
At the time of presentation, 55.5% of the 110 patients
with acute complicated aortic dissection type B showed
signs of malperfusion and 53.6% appeared with an aortic
rupture, both of which were present in 11 acute patients
(10%). Forty-three patients (39%) suffered from pain at
presentation, and four patients (3.6%) were intubated
before intervention. Only one patient presented with a pre-
interventional neurologic deﬁcit (paraparesis) (Table IV).
Of the 61 patients (55.5%) with signs of malperfusion as
a complication of the type B dissection, recorded malperfu-
sions were as follows: 12 (19.7%) extremity malperfusions,
12 (19.7%) mesenteric malperfusions, seven (11.5%) renal
malperfusions, one (1.6%) combined renal and mesenteric
malperfusion, and one (1.6%) spinal malperfusion; unfortu-
nately, in the remaining 28 (45.9%) cases, the details of
malperfusion were not recorded.
Intervention details and postinterventional outcome
are depicted in Table V. Femoral access was the access of
choice and was used in 106 patients (96%). In four patients
(3.6%), the femoral vessels were regarded as too small
(<0.8 mm), and therefore an iliac access was used. In 19patients (17.3%), the subclavian artery had to be over-
stented. Additional procedures were performed in 15 pa-
tients (13.6%): a second stent graft procedure in six
patients (5.4%), iliac stenting in two patients, fenestration
in two patients, left subclavian transposition in one patient,
complete arch debranching in one patient, carotid-
subclavian bypass in one patient, and infrarenal aortic
replacement in one patient (Table VI). Surgical interven-
tion/conversion was necessary in 11 patients (10.9%); six
patients underwent repair of retrograde type A aortic
dissection, two patients underwent thoracoabdominal
aortic replacement, two thoracotomies were performed
because of hemothorax, and one small bowel resection
was performed because of intestinal ischemia (Table VII).
Furthermore, nine patients (8%) developed an early type
I endoleak.
In ﬁve cases, a new permanent neurologic deﬁcit
occurred postinterventionally. One patient experienced a
stroke with permanent aphasia as the symptom, two pa-
tients had paraplegia, and two others had paraparesis.
Of the 97 patients surviving the hospital stay, we could
observe aneurysmal degeneration in 16 cases (16.5%). In
two cases, aneurysm development was proximal to the
stent graft; in the remaining 14, it was distal to it.
Postprocedural computed tomography angiography
showed complete thrombosis of the false lumen within
the thoracic portion of the descending aorta in 60.9% of
the patients. Complete thrombosis of the abdominal false
lumen was found in only 7.3% (Table V).
Actuarial survival at 1, 3, 5, and 10 years was 85%, 83%,
73%, and 65%, with 83, 62, 34, and 2 patients at risk,
respectively. Median follow-up was 37 months (0-144)
(Fig 1). Freedom from treatment failure according to the
Stanford classiﬁcation was 82%, 75%, and 59% at 1, 3,
and 5 years, respectively (Fig 2).
Fig 1. Overall survival of patients undergoing thoracic endovas-
cular aortic repair (TEVAR) for acute complicated type B aortic
dissection (acTBAD); median follow-up (FU): 37 months (0-144).
Fig 2. Freedom from treatment failure.
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Since the ﬁrst reports of successful treatment of patho-
logic processes of the descending thoracic aorta, optimism
was raised for improved early and long-term outcome.6,10
Nevertheless, recent reports in the scientiﬁc literature
revealed signiﬁcant difference in outcome of TEVAR accord-
ing to the indications, the patient’s comorbidities, and the
procedural aspects.11 The concept of stent graft placement
in type B aortic dissections is to seal the proximal entry tear,
to redirect ﬂow into the true lumen, and to promote depres-
surization and complete thrombosis of the false lumen.Ama-
jor advantage in comparison to surgical repair is the quick
relief of malperfusion syndrome. Surgical series on com-
plicated type B dissections, however, revealed impaired
outcome in comparison to other indications, with mortal-
ity rates ranging from 15% to 30% in complicated cases un-
der emergency conditions.12 Ever-growing experience
with TEVAR for aortic dissection conﬁrmed feasibility
and practicability, especially in unstable patients.13
Our multicenter analysis revealed that TEVAR for
acute complicated type B dissection is an effective approach
resulting in satisfying short- and long-term results. Most re-
ports in the scientiﬁc literature either contain complicated
as well as uncomplicated cases or report on a small number
of patients.14,15 Control of hypertension and pain as initial
therapy is already established and accepted as standard of
care in uncomplicated type B aortic dissections.
A major point of debate is deﬁnition of complicated
type B aortic dissection. Patients with ongoing or recurrent
pain are usually regarded as complicated and consecutively
switched from a conservative to an interventional or a sur-
gical treatment arm. This strategy was also used in the cen-
ters participating in this study; nevertheless, we excluded
patients with pain as the only criterion from our analysis.
The reason for this was to make a clear cutoff point: pain isa rather soft criterion from the patient’s point of view (less
or more sensitive to pain) as well as from the physician’s
standpoint (it can be overestimated and underestimated).
In contrast, rupture and malperfusion are objective criteria
for complicated type B dissections. Apart from that, these
patientsmight evenbe at higher risk than thosewith ongoing
pain but without signs of rupture and malperfusion. As
depicted in Table IV, 67% of our patients were clinically un-
stable at presentation; this shows that our subset of patients is
severely in danger. In our series, the overall in-hospital mor-
tality rate was 12%, which seems more than acceptable, tak-
ing into account this critical status.However, TEVAR is not
a treatment free from complications; 36% of our patients
experienced some kind of complication (including retro-
grade type A aortic dissection, neurologic deﬁcits, renal
dysfunction, and intestinal malperfusion) during their hos-
pital stay. Nevertheless, taking into account the preopera-
tive critical status of the majority of our patients, these
numbers are well within the acceptable range.
A major point of discussion is the retrograde type A
aortic dissection. In our series, we experienced six cases
(5.4%), which is a little bit higher than described in the sci-
entiﬁc literature. When taking a closer look at these patients,
we found that in all six cases, overstenting of the left subcla-
vian artery was performed. In our series, overstenting of the
left subclavian artery was performed in only 19 patients; in
this light, six retrograde type A dissections are a relatively
high number, even though it is still too low for ﬁnal statisti-
cal conclusions to be drawn. Obviously, involvement of the
distal arch or placement of the stent graft into or close to the
aortic arch seems to be a risk factor for retrograde type A
aortic dissection. The reason for this might be the disease it-
self or the design of the stent graft; especially early-
generation devices do not take into account the anatomic
conﬁguration of the aortic arch. In the six patients
with retrograde type A aortic dissection, two Talent,
three Gore, and one Valiant stent grafts were implanted.
However, because of the low overall number, it is not
JOURNAL OF VASCULAR SURGERY
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for retrograde type A dissection, and we can only speculate
that newer generation devices or even individually designed
devices, taking into account the individual anatomy of a pa-
tient’s arch, could reduce the risk for retrograde type A
aortic dissection. In our series, we also accepted patients
with landing zones <2 cm; in such cases, overstenting of
the left subclavian artery or a rerouting maneuver was per-
formed. An overall overstenting rate of 17% is low, but in
adding the rerouting cases, we end up at 19%, which is com-
parable to the scientiﬁc literature. It seems reasonable that
cases involving the distal arch with proximal landing zones
of <2 cm are at higher risk for retrograde type A aortic dis-
sections; nevertheless, six cases is too small a number for any
statistical conclusion to be drawn.
Another important outcome parameter apart from pure
survival is neurologic outcome. Within our series, ﬁve pa-
tients (4.5%) experienced new permanent neurologic deﬁ-
cits. A matter of debate regarding neurologic outcome is
the length of the stent graft. In case of aortic rupture,
the strategy in all participating centers was to cover the
whole thoracic descending aorta with the stent graft. Tak-
ing this into account, the 4.5% neurologic deﬁcits seem
well within the acceptable range and support this strategy
for stent graft placement in rupture patients.
A major limitation of the study might be a medical cen-
ter effect. The smallest center included in the study treated
only two patients, whereas the largest center performed 52
procedures. Although the low-volume centers might still
be at the beginning of their experience and also their
learning curve, larger centers might have improved their per-
formance over time. On the other hand, inclusion of low-
volume centers is still worthwhile because this might reﬂect
the real-world setting; in the real world, there are smaller and
larger centers, with more or less experienced surgeons and
interventionalists performing the procedures. Apart from
that, there might be a time bias; early-generation devices
that were used in the ﬁrst period of the study might have
been more difﬁcult to place and might even have led to
some complications, whereas newer generation devices
may improve the early postoperative outcome. Nevertheless,
we were not able to show that one or another device leads to
more or fewer complications, but this might be because of
the low number of cases performed with some devices.
CONCLUSIONS
Taken together, our results indicate that in patients
with life-threatening complications of acute type B dissec-
tion, TEVAR could become the primary treatment modal-
ity to quickly alleviate severe malperfusion as well as aortic
rupture.
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